Clinical Trial Update: Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the immunogenicity of the U.S.-licensed meningococcal serogroup B vaccine Trumenba; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• Trumenba (rLP2086)

Snippet

Sponsor: UCSF Benioff Children's Hospital Oakland | Conditions: Meningococcal Infections | Phase 4 | Status: COMPLETED | Results posted: 2021-02-02